Cargando…
The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
Endoxifen has recently been identified as the predominant active metabolite of tamoxifen and is currently being developed as a novel hormonal therapy for the treatment of endocrine sensitive breast cancer. Based on past studies in breast cancer cells and model systems, endoxifen classically function...
Autores principales: | Gingery, Anne, Subramaniam, Malayannan, Pitel, Kevin S., Reese, Jordan M., Cicek, Muzaffer, Lindenmaier, Laurence B., Ingle, James N., Goetz, Matthew P., Turner, Russell T., Iwaniec, Urszula T., Spelsberg, Thomas C., Hawse, John R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031133/ https://www.ncbi.nlm.nih.gov/pubmed/24853369 http://dx.doi.org/10.1371/journal.pone.0098219 |
Ejemplares similares
-
Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
por: Hawse, John R., et al.
Publicado: (2013) -
Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
por: Wu, Xianglin, et al.
Publicado: (2011) -
TGF-β Inducible Early Gene 1 Regulates Osteoclast Differentiation and Survival by Mediating the NFATc1, AKT, and MEK/ERK Signaling Pathways
por: Cicek, Muzaffer, et al.
Publicado: (2011) -
Retinoblastoma binding protein-1 (RBP1) is a Runx2 coactivator and promotes osteoblastic differentiation
por: Monroe, David G, et al.
Publicado: (2010) -
ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer
por: Reese, Jordan M, et al.
Publicado: (2014)